Enterprise Value

177.3B

Cash

5.688B

Avg Qtr Burn

N/A

Short % of Float

0.12%

Insider Ownership

0.06%

Institutional Own.

14.42%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Arexvy Details
Viral infection, Respiratory syncytial virus, Vaccine

Approved

Update

Jemperli (dostarlimab) Details
Cancer, Endometrial cancer

Approved

Quarterly sales

Jesduvroq (Daprodustat) Details
Chronic kidney disease

Approved

Quarterly sales

Approved

Quarterly sales

Arexvy Details
Vaccine, Respiratory syncytial virus, Viral infection

PDUFA

Approval decision

Jemperli (dostarlimab) Details
Cancer, Endometrial cancer

BLA

Submission

Phase 3

Data readout

Bepirovirsen Details
Hepatitis B vaccine

Phase 3

Data readout

Depemokimab Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Nucala Details
Chronic obstructive pulmonary disease

Phase 3

Data readout

Phase 3

Data readout

Linerixibat Details
Primary biliary cholangitis

Phase 3

Data readout

Cobolimab Details
Lung cancer, Non-small cell lung carcinoma, Cancer, Solid tumor/s

Phase 3

Data readout

Zejula Details
Cancer, Solid tumor/s, Lung cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Phase 3

Data readout

Zejula Details
Solid tumor/s, Cancer, Platinum-resistant ovarian cancer, Ovarian cancer

Phase 3

Data readout

Gepotidacin Details
Prevention of gonorrhea

Phase 3

Update

Phase 3

Update